Tagged with OP

Opinion Dr Neil Cashman examines the recent news around Biogen’s Alzheimer’s treatment aducanumab, assuages some investor fears, and underlines the treatment’s solid fundamentals and potential.    On April 2020, Biogen initiated regulatory review for aducanumab, its investigational therapy for Alzheimer’s disease. Investors reacted negatively, and this reverberated throughout the Alzheimer’s research…

Coronavirus Takeda’s Head of R&D Patient Engagement Jessica Scott examines the parallels between partnering with patients and working remotely with colleagues in the time of COVID-19.   Patients need us to engage with them, ask questions and listen. Just as we’re experiencing now with our own work relationships with colleagues, deeper…

Morocco In 2020, PharmaBoardroom has met with stakeholders from across the Moroccan healthcare and life sciences industries. These interviewees range from general managers overseeing several countries in the region from a base in Morocco to association heads and key opinion leaders from the worlds of academia and policymaking. Several recurring themes…

Cell & Gene Therapy Deloitte’s Omkar Kawalekar, Hussain Mooraj, and Amit Agarwal examine the evolution and future of cell and gene therapy manufacturing and the areas in which biopharma firms need to invest in order to succeed in this emergent field.   Cell and gene therapies (CGT) are the next evolution of personalized health…

Coronavirus Sophia Ononye-Onyia outlines the key failings in the USA’s response to the coronavirus outbreak and why greater numbers of inter-industry partnerships and increased technological uptake are key to fighting this crisis and reframing the US life sciences industry of the future.   Imagine if we invested billions in epidemiological surveillance…

Belgium In 2020 PharmaBoardroom sat down with several key stakeholders in Belgian pharma to discuss company strategy, the Belgian healthcare landscape at large, and the country’s role within the wider European and global ecosystem. Here we highlight some of the key themes of the discussions: innovation, generics and biosimilars, and teamwork.…

Belgium Dirk Reyn of Flanders.bio highlights what the Flanders region has to offer the life sciences and biotech industries in terms of research infrastructure, funding opportunities, and inter-industry collaboration.   In the biotech/agro and foodtech area, Belgium and Flanders are in a very dynamic and positive period and we expect to…

Opinion Song Ruilin, chairman of the China Pharmaceutical Innovation and Research Development Association (PhIRDA) highlights the leaps and bounds with which the Chinese pharmaceutical industry has developed in recent years, the country’s increasingly important role in the global innovation landscape, and why cross-border collaboration is more crucial than ever in the…

Mexico Here we highlight the top 10 pharma companies in Mexico based on IQVIA data from February MAT 2020. Four of the top ten companies are Mexican: PISA, Sanfer, Senosiain and Siegfried Rhein.   Made with Visme Infographic Maker

Opinion John G. Singer examines how the ongoing coronavirus pandemic may create a new dichotomy for global healthcare – and why pharma companies still wedded to the market models of the past risk getting left behind.   “Drug” companies have a unique opportunity to invent a different market for themselves. It…

Belgium Miguel Forte, CEO of Bone Therapeutics, walks through his journey leading the promising Belgian biotech company. He also shares with his view of the Belgian healthcare system and what makes the country a perfect environment for Bone Therapeutics as a biotech company focusing on innovative cell and gene therapy.  …

Coronavirus Shawview Consulting’s Brendan Shaw makes a compelling case for why the ongoing coronavirus pandemic should lead to a rethinking of how healthcare works across the globe.   Global crises can trigger major reform and Covid19 should trigger a reform of our health systems.   9/11 and the GFC When two…